SCM
ALLO icon

Sterling Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Sterling Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1K Buy
5,349
+100
+2% +$220 ﹤0.01% 2165
2026
Q1 		$12.8K Sell
5,249
-3,617
-41% -$7.25K ﹤0.01% 2244
2025
Q4 		$12.1K Sell
8,866
-1,596
-15% -$2.1K ﹤0.01% 2508
2025
Q3 		$13K Buy
10,462
+6,836
+189% +$8.15K ﹤0.01% 2351
2025
Q2 		$4.1K Buy
3,626
+1,411
+64% +$1.88K ﹤0.01% 2619
2025
Q1 		$3.23K Sell
2,215
-1,897
-46% -$3.58K ﹤0.01% 2377
2024
Q4 		$8.76K Buy
4,112
+3,663
+816% +$9.03K ﹤0.01% 2225
2024
Q3 		$1.26K Buy
+449
New +$1.2K ﹤0.01% 2411

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Sterling Capital Management's ALLO Position: Q2 2026 in Review

Sterling Capital Management increased its Allogene Therapeutics (ALLO) stake by 1.9% in Q2 2026, buying an estimated $220 and bringing the position to 5,349 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2165.

Sterling Capital Management first reported a position in ALLO in Q3 2024 and has held it in 8 quarters since. The position peaked at $13K in Q3 2025. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Sterling Capital Management held 5,349 shares of Allogene Therapeutics worth $11.1K as of Q2 2026.
  • Sterling Capital Management bought 100 Allogene Therapeutics shares in Q2 2026, an estimated $220.
  • Allogene Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2165 holding.
  • Sterling Capital Management first reported a position in Allogene Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Allogene Therapeutics position peaked at $13K in Q3 2025.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.